Cargando…
Use of health technology assessment in drug reimbursement decisions in China
China has made substantial progress in using health technology assessment, but more effort should be made to improve the quality of evidence, strengthen capacity, and enhance transparency, say Wen Chen and colleagues
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BMJ Publishing Group Ltd.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266437/ https://www.ncbi.nlm.nih.gov/pubmed/37321619 http://dx.doi.org/10.1136/bmj-2021-068915 |
| _version_ | 1785058740752351232 |
|---|---|
| author | Chen, Wen Zhang, Luying Hu, Min Hu, Shanlian |
| author_facet | Chen, Wen Zhang, Luying Hu, Min Hu, Shanlian |
| author_sort | Chen, Wen |
| collection | PubMed |
| description | China has made substantial progress in using health technology assessment, but more effort should be made to improve the quality of evidence, strengthen capacity, and enhance transparency, say Wen Chen and colleagues |
| format | Online Article Text |
| id | pubmed-10266437 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | BMJ Publishing Group Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-102664372023-06-15 Use of health technology assessment in drug reimbursement decisions in China Chen, Wen Zhang, Luying Hu, Min Hu, Shanlian BMJ Analysis China has made substantial progress in using health technology assessment, but more effort should be made to improve the quality of evidence, strengthen capacity, and enhance transparency, say Wen Chen and colleagues BMJ Publishing Group Ltd. 2023-06-15 /pmc/articles/PMC10266437/ /pubmed/37321619 http://dx.doi.org/10.1136/bmj-2021-068915 Text en © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
| spellingShingle | Analysis Chen, Wen Zhang, Luying Hu, Min Hu, Shanlian Use of health technology assessment in drug reimbursement decisions in China |
| title | Use of health technology assessment in drug reimbursement decisions in China |
| title_full | Use of health technology assessment in drug reimbursement decisions in China |
| title_fullStr | Use of health technology assessment in drug reimbursement decisions in China |
| title_full_unstemmed | Use of health technology assessment in drug reimbursement decisions in China |
| title_short | Use of health technology assessment in drug reimbursement decisions in China |
| title_sort | use of health technology assessment in drug reimbursement decisions in china |
| topic | Analysis |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266437/ https://www.ncbi.nlm.nih.gov/pubmed/37321619 http://dx.doi.org/10.1136/bmj-2021-068915 |
| work_keys_str_mv | AT chenwen useofhealthtechnologyassessmentindrugreimbursementdecisionsinchina AT zhangluying useofhealthtechnologyassessmentindrugreimbursementdecisionsinchina AT humin useofhealthtechnologyassessmentindrugreimbursementdecisionsinchina AT hushanlian useofhealthtechnologyassessmentindrugreimbursementdecisionsinchina |